1
|
Lovato N, Santiago Padilla L. Therapeutics and prospects of Interleukin 2. BIONATURA 2019. [DOI: 10.21931/rb/2019.04.04.13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Interleukin-2 was discovered back in 1983 as an autocrine growth factor for cultured T cells and was the first biological product created through the use of recombinant DNA. IL-2 tumor immunotherapy performed the first historical clinical demonstration of the possibility to cause an effective anticancer immune reaction, mediated by cytotoxic lymphocytes activated from IL-2 stimulation. The Interleukin 2 receptor is a heterotrimeric protein that is composed of three peptide chains: the alpha chain, the beta chain and the gamma chain of the common cytokine receptor. There are 3 majors’ ways of interfering with the IL-2/IL-2R to use it as treatments: Antibodies, Aptamers, and punctual mutagenesis. Recent studies have shown, that Il-2 therapies for cancer, specifically targets restoring the individual’s natural antitumor immune response. HIV directed treatments have demonstrated the necessity of introducing the IL-2 complemented with the patient’s antiretroviral therapy.
Collapse
Affiliation(s)
- Nicole Lovato
- Yachay University of Experimental Technological Research. Ecuador
| | | |
Collapse
|
2
|
Bonfanti A, Lissoni P, Bucovec R, Rovelli F, Brivio F, Fumagalli L. Changes in Circulating Dendritic Cells and IL-12 in Relation to the Angiogenic Factor VEGF during IL-2 Immunotherapy of Metastatic Renal Cell Cancer. Int J Biol Markers 2018; 15:161-4. [PMID: 10883890 DOI: 10.1177/172460080001500206] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Angiogenesis and immunosuppression are the main biological mechanisms responsible for cancer progression. Moreover, recent observations suggesting a negative influence of angiogenesis on anticancer immunity have shown that some angiogenic factors, such as VEGF, may induce immunosuppression. In addition, the evidence of abnormally high blood levels of VEGF has been proven to be associated with resistance to IL-2 immunotherapy. The present study was performed to establish a possible relation ship between the efficacy of IL-2 cancer immunotherapy and changes in circulating levels of VEGF, IL-12, mature and immature dendritic cells (DC). The study included 25 metastatic renal cell cancer patients who underwent subcutaneus low-dose IL-2 immunotherapy (6 MIU/day for 6 days/week for 4 weeks). Immature and mature DCs were identified as CD123+ and CD11c+ cells, respectively. The clinical response consisted of partial response (PR) in five, stable disease (SD) in 11 and progressive disease (PD) in the remaining nine patients. The mean IL-12 levels observed during IL-2 immunotherapy were significantly higher in patients with PR or SD than in those with PD, whereas the mean VEGF concentrations were significantly higher in patients who had PD than in those with PR or SD. Finally, a significant increase in the mean number of circulating mature DCs occurred only in patients with PR or SD, whereas no significant change was seen in patients with PD. By contrast, no significant change was observed in the mean number of immature DCs. This study shows that the efficacy of IL-2 immunotherapy is associated with a significant increase in circulating mature DCs and IL-12, without any concomitant increase in VEGF concentrations. Further studies will be required to better define the relationship between activation of anticancer immunity and control of angiogenesis-related mechanisms.
Collapse
Affiliation(s)
- A Bonfanti
- Division of Radiation Oncology, S. Gerardo Hospital, Monza (MI), Italy
| | | | | | | | | | | |
Collapse
|
3
|
Affiliation(s)
- Paolo Lissoni
- Department of Oncological Service, Institute of Biological Medicine, Milan, Italy
| |
Collapse
|
4
|
Lissoni P, Rovelli F. Principles of psychoneuroendocrinoimmunotherapy of cancer. Immunotherapy 2012; 4:77-86. [PMID: 22150002 DOI: 10.2217/imt.11.158] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
Recent advances in the knowledge of the mechanisms responsible for antitumor immunity have stimulated the elaboration of new cancer immunotherapeutic strategies. Moreover, more recent discoveries have demonstrated that immune responses are under a physiological modulatory control played by several neuroendocrine pathways, which explain the differences between the in vivo and in vitro immune responses. While until a few years ago the evaluation of the immune status of cancer patients was substantially established on the basis of clinical empirical criteria, recent discoveries of the antitumor cytokine network have allowed the biochemical bases of anticancer immunity to be defined, leading to new anticancer immunotherapeutic strategies, on the basis of patient neuroendocrine and neuroimmune status, in an attempt to correct the great number of cancer-related alterations on the basis of knowledge of the physiopathology of anticancer immunity. The rationale for cancer neuroimmunotherapy consists of the possibility to enhance the efficacy of the various immunotherapeutic strategies by a concomitant administration of antitumor cytokines (namely IL-2), in addition to neuroendocrine endogenous molecules (namely the pineal indole hormones), able to stimulate the anticancer immunoresponse by amplifying the anticancer reaction and/or by counteracting the generation of immunosuppressive events.
Collapse
|
5
|
|
6
|
Baaten G, Voogd AC, Wagstaff J. A systematic review of the relation between interleukin-2 schedule and outcome in patients with metastatic renal cell cancer. Eur J Cancer 2004; 40:1127-44. [PMID: 15110876 DOI: 10.1016/j.ejca.2004.02.010] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2004] [Accepted: 02/05/2004] [Indexed: 01/11/2023]
Abstract
In Europe, interleukin 2 (IL-2) is one of the two treatment modalities officially approved for patients with metastatic renal cell cancer. Traditionally, IL-2 has been administered by three different routes: intermittent bolus injection (BIV), continuous intravenous infusion (CIV) and subcutaneous injection (SC). There have been few randomized trials designed to compare these routes of administration. This paper describes a systematic review of the literature in which an attempt has been made to determine which schedule of administration is superior. Heterogeneity of the data makes firm conclusions difficult. It appears that the number of complete remissions (CR) is similar between BIV and SC routes and that these are higher than for CIV schedules. The durability of the CRs induced by BIV appeared superior to those induced by SC IL-2 and definitely higher than with CIV protocols. This analysis highlights some of the difficulties of using evidence-based medicine to determine standard of care when the clinical-trial data are heterogeneous. These data emphasize the importance of randomized clinical trials in determining what should be regarded as optimum therapy.
Collapse
Affiliation(s)
- G Baaten
- Faculty of Medicine, University of Maastricht, Maastricht, The Netherlands
| | | | | |
Collapse
|
7
|
Lissoni PAOLO, Bonfanti ANGELA, Bordin VERONICA, Barni SANDRO, Vigore LUIGI, Ferrante ROBERTO, Rovelli FRANCO, Fumagalli LUCA. Malignancy: Changes in Circulating Immature and Mature Dendritic Cells During IL-2 Cancer Immunotherapy and Their Relation with Lymphocyte Increase and Clinical Response. HEMATOLOGY (AMSTERDAM, NETHERLANDS) 2001; 5:117-125. [PMID: 11399607 DOI: 10.1080/10245332.2000.11746494] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
Lymphocytosis is the main biomarker predicting the efficacy of subcutaneous IL-2 anticancer immunotherapy. In addition, it has been demonstrated the fundamental role of dendritic cells (DC) in the generation of an effective anticancer immunity. However, the relation between IL-2 and DC system needs to be further understood. This preliminary study was performed in an attempt to analyze changes in circulating DC during IL-2 cancer immunotherapy in relation to lymphocyte variations and clinical efficacy of treatment. The study included 20 metastatic renal cell cancer patients, who underwent subcutaneous low-dose IL-2 immunotherapy (6.000.000 IU/day for 6 days/week for 4 weeks). To evaluate DC, venous blood samples were collected before and after 2 weeks of IL-2 injections, corresponding to the period of maximum lymphocytosis. Immature (CD123(+) ) and mature (CD11c(+) ) DC were measured by FACS and monoclonal antibodies. IL-2 induced a significant increase in the mean number of circulating mature DC, whereas no substantial change occurred in immature DC mean number. The increase in mature DC was associated with a control of disease, whereas no rise was observed in patients who had progressed on IL-2 immunotherapy. Moreover, the increase in mature DC mean number was significantly higher in patients showing evident lymphocytosis, with lymphocyte enhancement greater than 1000 cells/mmc, than in patients with less pronounced lymphocytosis, even though no significant correlation was seen in between mature DC and lymphocyte increase. This preliminary study would suggest that IL-2 may stimulate DC system and that the clinical anticancer efficacy of IL-2 is associated with the increase in circulating mature DC, which could be considered as a new favourable biomarker during IL-2 immunotherapy.
Collapse
Affiliation(s)
- PAOLO Lissoni
- Division of Radiation Oncology, San Gerardo Hospital, Monza (Milano) Italy
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Lissoni P, Rovelli F, Vellani D, Malugani F, Bucovec R, Chapovalenko L, Fumagalli E, Gardani G. Stimulation of IL-18 Secretion by IL-2 in Patients with Advanced Cancer. Int J Biol Markers 2001; 16:146-7. [PMID: 11471899 DOI: 10.1177/172460080101600211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
9
|
Bönig H, Laws HJ, Wundes A, Verheyen J, Hannen M, Kim YM, Banning U, Nürnberger W, Körholz D. In vivo cytokine responses to interleukin-2 immunotherapy after autologous stem cell transplantation in children with solid tumors. Bone Marrow Transplant 2000; 26:91-6. [PMID: 10918410 DOI: 10.1038/sj.bmt.1702431] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The potent immunostimulatory cytokine interleukin-2 (IL-2) has been extensively investigated for its potential to induce anti-tumor immunity in a number of tumor models. Only recently the complex interplay of mutually suppressive or supportive cytokines of the IL-2-induced network of cytokines has been better characterized. The aim of this study was to assess which of these in vitro findings are reproducible in vivo in recipients of stem cell transplants (SCT), since in these patients long- lasting impairments in cytokine inducibility have been described. We have therefore studied the kinetics of putative modulators and mediators of IL-2-induced immune activation, namely IL-1beta, IL-4, IL-5, IL-10, IL-12, soluble Fas ligand (sFasL), and GM-CSF during IL-2 therapy. All patients were children or adolescents suffering from solid tumors with poor prognosis who received three 5-day courses of high-dose intravenous IL-2 as an adjuvant to their radio-chemotherapy and autologous SCT. While IL-1beta, IL-4 and IL-12 were not, and sFasL was only mildly affected by the IL-2 therapy, we observed a consistent and early rise of IL-10, IL-5, and GM-CSF. These increases were rapidly reversible after discontinuation of IL-2 therapy. The inducibility of IL-10, IL-5 and GM-CSF was more pronounced with increasing time from the SCT, and in the third cycle reached an order of magnitude as in high-dose IL-2 patients without SCT. Together with the abundant in vitro data, these findings may help devise a combination immunotherapy permitting stronger anti-tumor effects, but lesser adverse effects.
Collapse
Affiliation(s)
- H Bönig
- Department of Pediatric Hematology and Oncology, Center of Child Health, Heinrich-Heine University Medical Center, Düsseldorf, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Lissoni P, Bucovec R, Meregalli S, Fumagalli L, Vigorè L, Ferrante R, Brivio F. IL-2 Immunotherapy-Induced Increase in IL-12 Blood Concentrations May Depend on an Increase in Circulating Dendritic Cell Number. Int J Biol Markers 1999; 14:195-7. [PMID: 10569145 DOI: 10.1177/172460089901400314] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
11
|
Lissoni P, Rovelli F, Mandalà M, Barni S. Blood Concentrations of Interleukin-15 in Cancer Patients and Their Variations during Interleukin-2 Immunotherapy: Preliminary Considerations. Int J Biol Markers 1998; 13:169-71. [PMID: 10079393 DOI: 10.1177/172460089801300309] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
In addition to the better known cytokines IL-2 and IL-12, IL-15, which is mainly produced by macrophages, is a new antitumor cytokine with a mechanism of action similar to that of IL-2. At present, however, there are no data about IL-15 secretion in cancer patients. This study was carried out to evaluate IL-15 blood concentrations in patients with early or advanced cancer and their possible variations in response to IL-2 cancer immunotherapy. The study included 40 patients with solid tumors, 24 of whom had metastatic disease. In addition, IL-15 secretion was evaluated during subcutaneous low-dose IL-2 therapy (6 million IU/day for 6 days/week for 4 weeks) in 14 metastatic renal cell cancer patients by collecting blood samples at weekly intervals. The control group consisted of 40 age-matched healthy subjects. Serum levels of IL-15 were measured by an enzyme immunoassay. No significant difference in mean serum levels of IL-15 was observed between cancer patients and controls. Moreover, the mean serum levels of IL-15 found in metastatic cancer patients were not significantly different from those found in patients with limited disease. Finally, no significant changes in mean levels of IL-15 occurred during IL-2 cancer immunotherapy. This preliminary study would suggest that IL-15 secretion is substantially within the normal range in cancer patients, both in early and advanced disease, and no variation seems to occur in response to IL-2 administration.
Collapse
Affiliation(s)
- P Lissoni
- Division of Radiation Oncology, S. Gerardo Hospital, Monza, MI, Italy
| | | | | | | |
Collapse
|